Gujarat Themis Biosyn Limited (NSE:GUJTHEM)
455.05
+2.75 (0.61%)
At close: Oct 24, 2025
Gujarat Themis Biosyn Revenue
Gujarat Themis Biosyn had revenue of 358.73M INR in the quarter ending June 30, 2025, a decrease of -7.61%. This brings the company's revenue in the last twelve months to 1.48B, down -7.05% year-over-year. In the fiscal year ending March 31, 2025, Gujarat Themis Biosyn had annual revenue of 1.51B, down -11.20%.
Revenue (ttm)
1.48B
Revenue Growth
-7.05%
P/S Ratio
33.54
Revenue / Employee
6.69M
Employees
221
Market Cap
49.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.51B | -190.22M | -11.20% |
| Mar 31, 2024 | 1.70B | 214.37M | 14.45% |
| Mar 31, 2023 | 1.48B | 335.31M | 29.19% |
| Mar 31, 2022 | 1.15B | 242.91M | 26.82% |
| Mar 31, 2021 | 905.63M | 54.38M | 6.39% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |